Please login to the form below

Not currently logged in
Email:
Password:

Jetrea

This page shows the latest Jetrea news and features for those working in and with pharma, biotech and healthcare.

Novartis' Lucentis wins fourth NICE recommendation

Novartis' Lucentis wins fourth NICE recommendation

The NICE recommendation is the second in the space of a week for Novartis, which two days ago received a green light for Jetrea (ocriplasmin) to treat patients with the rare

Latest news

  • NICE backs Novartis/ ThromboGenics’ eye drug NICE backs Novartis/ ThromboGenics’ eye drug

    Recommends Jetrea for NHS use in England and Wales to treat the rare disease vitreomacular traction. ... NICE's recommendation limits use of Jetrea compared to its European approval, which covers all vitreomacular traction patients.

  • NICE backs Novartis' Jetrea in rare eye condition NICE backs Novartis' Jetrea in rare eye condition

    This differs from its licence from the European Medicines Agency (EMA), which in March 2013 approved the use of Jetrea in any adult with the condition. ... Once launched, Jetrea will be marketed by Novartis' eye division Alcon, which purchased non-US

  • Alcon wins initial NICE backing for Jetrea in rare eye condition Alcon wins initial NICE backing for Jetrea in rare eye condition

    It purchased the rights to commercialise Jetrea outside the US from its developers ThromboGenics in 2012 as part of a deal potentially worth up to 375m. ... In addition to its European licence, Jetrea won approval in October last year for the treatment

  • Novartis, ThromboGenics' eye drug Jetrea gets green light in EU Novartis, ThromboGenics' eye drug Jetrea gets green light in EU

    Jetrea was approved for symptomatic VMA last year in the US, where ThromboGenics has retained exclusive commercial rights, and was launched onto the market in January 2013. ... Analysts have suggested Jetrea sales could reach $500m in the US alone, with

  • Novartis' eye drug Jetrea recommended for EU approval Novartis' eye drug Jetrea recommended for EU approval

    European regulatory authorities have backed Novartis' licence application for its new eye drug Jetrea (ocriplasmin). ... world.". Jetrea is a recombinant form of human protein (plasmin) that is administered through a one-time, single intravitreal

More from news
Approximately 4 fully matching, plus 2 partially matching documents found.

Latest appointments

  • ThromboGenics bolsters leadership team ThromboGenics bolsters leadership team

    Vangeersdaele will be leading and developing the overall commercial strategy for the company’s recently formed Jetrea business unit, which was created following ThromboGenics regaining full rights to Jetrea from Novartis. ... I am convinced that their

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Founded in 2015, Windrose Consulting Group is a privately-held global strategy firm that partners with life science companies to maximize...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....